書誌事項
- タイトル別名
-
- Expression of Post-Merger Effect in R&D Function of Japanese Pharmaceutical Companies
- セイヤク キギョウ ノ ケンキュウ カイハツ キノウ ニ オケル キギョウ ガッペイ トウゴウ コウカ ノ ハツゲン ヨウシキ アステラス セイヤク ノ ジレイ
- A Case Study of Astellas Pharma
- アステラス製薬の事例
この論文をさがす
抄録
In this study we investigated the effect of corporate merger and acquisition (M&A) on the uptake and diffusion of innovation in pharmaceutical research and development (R&D) from the viewpoint of corporate organization management. Here we selected a case of Astellas Pharma and observed its post-merger management (PMM) effects on the size of R&D, research efficiency and licensing efficiency for two years after the establishment. Through a series of in-depth internal interviews and analyses we found a significant diversification of technological opportunities created by the complementary effects of the M&A which may lead to inconsistent gains in research and licensing efficiencies. We also observed a considerable fit between these effects and the corporate vision and strategy that the management had initially intended. Precedent studies indicated that the positive effect of M&A tends to be limited to short-term impacts such as fulfillment of pipeline candidates. Our study suggests the significance of PMM and monitoring approaches from the economy of scope rather than the economy of scale for long-lasting effects on pharmaceutical R&D.
収録刊行物
-
- 医療と社会
-
医療と社会 18 (2), 273-289, 2008
公益財団法人 医療科学研究所
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390282679449574656
-
- NII論文ID
- 130004547637
-
- NII書誌ID
- AN10372213
-
- ISSN
- 18834477
- 09169202
-
- NDL書誌ID
- 9597083
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可
